Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
L. Segú, P. Solans, P. Gavilán, I. Vargas, B. Ruiz, C. Manté.
La utilització de medicaments; la perspectiva dels proveïdors.
Fulls Económics del Sistema Sanitari, 33 (1999), pp. 18-23
[2.]
F. Lobo.
La creación de un mercado de medicamentos genéricos en España.
La regulación de los servicios sanitarios en España, pp. 393-430
[3.]
El sector farmacéutico en Alemania.
Las reformas sanitarias y su impacto en la industria farmacéutica.
Oficina de Economía de la Salud, Farmaindustria, (1996),
[4.]
Le Pen C. European drugs prices: old and new models. Preliminary version.
[5.]
F.E. Munnich, K. Sullivan.
The impact of the recent legislative change in Germany.
Pharmacoeconomics, 6 (1994), pp. 22-27
[6.]
P. Zweiffel, L. Crivelli.
Price regulation of drugs: lessons from Germany.
J Regul Econ, 10 (1996), pp. 257-273
[7.]
H. Rigter.
Recent public policies in the Netherlands to control pharmaceutical pricing and reimbursement.
Pharmacoeconomics, 6 (1994), pp. 15-21
[8.]
M. Cornelis.
The 1996 pricing and reimbursement policy in the Netherlands.
Pharmacoeconomics, 10 (1996), pp. 75-80
[9.]
J. Clausen.
Financing of prescription drugs in Denmark: alternative designs of the reimbursement system.
Poster presented at the Third European Conference on Health Economics,
[10.]
B. Jönsson.
Cost sharing for pharmaceuticals: the Swedish reimbursement system.
Pharmacoeconomics, 10 (1996), pp. 68-74
[11.]
B. Jönsson.
Pricing and reimbursement of pharmaceuticals in Sweden.
Pharmacoeconomics, 6 (1994), pp. 51-60
[12.]
G. López, J. Puig.
Review of the literature on reference pricing.
Health Policy, 54 (2000), pp. 87-123
[13.]
N. Freemantle, K. Bloor.
Leassons from international experience in controlling pharmaceutical expenditure I: Influencing patients.
BMJ, 312 (1996), pp. 1469-1471
[14.]
N. Freemantle, K. Bloor.
Leassons from international experience in controlling pharmaceutical expenditure II: Influencing doctors.
BMJ, 312 (1996), pp. 1525-1527
[15.]
N. Freemantle, K. Bloor.
Leassons from international experience in controlling pharmaceutical expenditure III: Regulating Industry.
BMJ, 313 (1996), pp. 33-35
[16.]
M. Dickson, H. Redwood.
Pharmaceutical reference prices. How do they work in prectice?.
Pharmacoeconomics, 14 (1998), pp. 471-479
[17.]
V. Ulrich, E. Wille.
Healthcare reform and expenditure on drugs: the German situation.
Pharmacoeconomics, 10 (1996), pp. 81-88
[18.]
O. Schoffski.
Consequences of implementing a drug budget for office-based physicians in Germany.
Pharmacoeconomics, 10 (1996), pp. 37-47
[19.]
L. Narine, M. Senathirajah, T. Smith.
Evaluating reference-based pricing: initial findings and prospects.
CMAJ, 161 (1999), pp. 286-288
[20.]
T. Cueni.
An industrial policy for the pharmaceutical industry in Europe.
The way forward, in health care reforms and the role of the pharmaceutical industry,
[21.]
S. Muñio.
Influencia de los precios de referencia en la industria farmacéutica.
Farma Forum 2000. III Encuentro del Sector Farmacéutico Español,
[22.]
L. Segú, C. Zara.
El sistema de preus de referència com a mecanisme de regulació del mercat farmacèutic: descripció, impactes i aplicabilitat a Espanya.
Bioètica i Debat Monogràfic, (1997; oct), pp. 1-32
[23.]
F. Plaza.
Precios de referencia, 22.000 millones de ahorro anual.
El Global, 10 (2000), pp. 4
[24.]
D.L. Baines, D.K. Whynes, K.H. Tolley.
General practitioner fundholding and prescribing expenditure control: evidence from a rural english health authority.
Pharmacoeconomics, 11 (1997), pp. 350-358
[25.]
A. Towse.
The pricing and reimbursement of pharmaceuticals.
Pharmacoeconomics, 6 (1994), pp. 36-38
[26.]
N. Bosanquet, J. Zammit-Lucia.
The effect of competition on drug prices.
Pharmacoeconomics, 8 (1995), pp. 473-478
[27.]
T.J.B. Maling.
The New Zeland preferred medicins concept: a national scheme for audit and quality assurance prescribing.
Pharmacoeconomics, 6 (1994), pp. 5-14
[28.]
S. Stewart-Brown, R. Surender, J. Bradlow, A. Coulter, H. Doll.
The effects of fundholding in general practice on prescribing habits three years after introduction of the scheme.
BMJ, 311 (1995), pp. 1543-1547
Este trabajo ha sido parcialmente reproducido del encargo solicitado por la Fundación Institut Borja de Bioética.
Copyright © 2001. Elsevier España, S.L.. Todos los derechos reservados
